<DOC>
	<DOCNO>NCT01524770</DOCNO>
	<brief_summary>The study involve 2 injection 1.5 milligram ( mg ) dulaglutide , 1 give pre-filled manual syringe , give auto-injector . Injections separate minimum 28-day washout period . The study evaluate level drug blood similar give method . Participation study likely take approximately 7 week , include screening .</brief_summary>
	<brief_title>A Study Compare Effect Giving Dulaglutide Using Auto-injector Versus Manual Syringe</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Are overtly healthy male female , determine medical history physical examination Male participant female partner childbearing potential partner pregnant breastfeed agree use reliable method contraception time first dose 3 month last dose investigational product , determine investigator The method may one following : condom spermicidal agent male participant sterilization true abstinence ( line participant 's usual lifestyle choice ; withdrawal calendar method consider acceptable ) Female participant childbearing potential ( , postmenopausal permanently sterilize [ , tubal occlusion , hysterectomy , bilateral salpingectomy , bilateral oophorectomy ] ) . Such participant require use contraception must test negative pregnancy time enrollment Postmenopausal define least 1 year post cessation menses ( without alternative medical cause ) spontaneous amenorrhea 6 12 month , follicle stimulate hormone ( FSH ) â‰¥40 milliinternational unit per milliliter ( mIU/mL ) Female participant undergone sterilization tubal ligation agree use condom conjunction spermicidal gel , foam , cream , film suppository time screen 3 month last dose investigational product . Such participant must also test negative pregnancy time enrollment Have body mass index ( BMI ) 18.5 32.0 kilogram per meter square ( kg/m^2 ) , inclusive , screen Have clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator Have venous access sufficient allow blood sample per protocol Are reliable willing make available duration study willing follow study procedure willing follow study restriction Have give write informed consent approve Lilly ethical review board ( ERB ) govern site Are currently enrol complete discontinue within last 30 day clinical trial involve investigational product , concurrently enrol type medical research judge scientifically medically compatible study Have know allergy Glucagonlike peptide 1 ( GLP1 ) relate compound include dulaglutide , component formulation Are person previously complete withdrawn study study investigate dulaglutide 3 month prior screen receive glucagonlike peptide incretin mimetics 3 month prior screen Have abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study Have abnormal blood pressure ( least 5 minute sit ) , opinion investigator , increase risk associate participate study Have history presence cardiovascular , respiratory , hepatic , renal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data Have history presence pancreatitis ( history chronic pancreatitis idiopathic acute pancreatitis ) gastrointestinal disorder , example relevant esophageal reflux gall bladder disease , gastrointestinal disease impact gastric emptying ( , gastric bypass surgery , pyloric stenosis , exception appendectomy ) could aggravate GLP1 analog . Participants dyslipidemia , participant cholecystolithiasis ( removal gall stone ) and/or cholecystectomy ( removal gall bladder ) past , sequela , may include study discretion screen physician Show evidence significant active neuropsychiatric disease Have family history medullary thyroid cancer ( MTC ) genetic condition predisposes MTC Regularly use know drug abuse and/or show positive finding urinary drug screen Show evidence human immunodeficiency virus ( HIV ) infection and/or positive human HIV antibody Show evidence hepatitis C and/or positive hepatitis C antibody Show evidence hepatitis B and/or positive hepatitis B surface antigen Are woman positive pregnancy test woman lactate Have use intend use overthecounter medication acetaminophen within 7 day prior dose prescription medication ( exception vitamin/mineral supplement and/or hormone replacement therapy [ HRT ] ) within 14 day prior dose Have donate blood 500 milliliter ( mL ) within last month Have average weekly alcohol intake exceed 21 unit per week ( male age 65 ) 14 unit per week ( male 65 female ) , unwilling adhere alcohol restriction ( 1 unit = 12 ounce [ oz ] 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) Smoke 10 cigarette ( equivalent nicotine ) per day , unwilling refrain smoking day dulaglutide administration unable abide clinical research unit ( CRU ) restriction In opinion investigator sponsor , unsuitable inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>